Droperidol found to be quickest in sedating acutely agitated patients.
In a double-blind, randomized trial involving a total of 147 patients who presented to an emergency department during the 2004-2005 study period, an intramuscular injection of 5 mg of the butyrophenone antipsychotic droperidol was found to result in significantly greater sedation after 15 and 30 minutes (as measured by mean scores on the Altered Mental Status Scale) than did 10 mg or 20 mg of the atypical antipsychotic ziprasidone (Geodon) or 2 mg of the benzodiazepine lorazepam.
Each group had similar levels of sedation between 45 minutes and 2 hours after administration, according to Dr. Gengerke, who presented the study in a poster session at the meeting.
Respiratory depression occurred more often in patients who had received 20 mg of ziprasidone than in patients of the other medication groups, although the rate of hypoxia did not differ significantly between the groups, wrote Dr. Gengerke, a first-year resident in emergency medicine at the Hennepin County Medical Center, Minneapolis.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Adult Psychiatry|
|Publication:||Clinical Psychiatry News|
|Article Type:||Brief article|
|Date:||Oct 1, 2005|
|Previous Article:||Schizophrenia prodrome therapies show promise: early intervention with antipsychotics and CBT appears to delay or prevent psychotic breaks.|
|Next Article:||Look for rigid thinking in psychotic depression.|